BOC International released a research report stating that it maintains Rongchang Biotech's (09995.HK) “buy” rating, with a target price of HK$56. The bank kept the company's profit forecast unchanged: revenue for 2024-26 reached 1.66 billion/2.50 billion/3.73 billion yuan respectively, net loss gradually narrowed, and break-even was achieved in 2027. The company has many catalysts in product commercialization, clinical data reading, mainland supervision and approval, and overseas travel in 2024.
交银国际：维持荣昌生物(09995.HK)“买入”评级 目标价56港元
BOC International: Maintaining Rongchang Biotech's (09995.HK) “Buy” Rating Target Price of HK$56
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.